Sign in or create an account to add this stock to your watchlist.
About ANI Pharmaceuticals (NASDAQ:ANIP)
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. It focuses on producing controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. The company offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and hydrocortisone enema and cortenema to treat ulcerative colitis. It also provides Hydrocortisone Rectal Cream to treat inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses; Lithium Carbonate ER and Lithobid for bipolar disorder; Mesalamine Enema to treat distal ulcerative colitis, proctosigmoiditis, or proctitis; Methazolamide to treat ocular conditions; and Metoclopramide and Reglan to treat gastroesophageal reflux. In addition, the company offers Nilutamide to treat metastatic prostate cancer; Nimodipine that reduces the ischemic deficits in patients with subarachnoid hemorrhage; Opium Tincture to treat diarrhea; Oxycodone capsules and oral solution for severe and chronic pain; Propafenone to treat arrhythmia; Propranolol ER, Inderal LA, and Pindolol for managing hypertension in patients with angina pectoris; and Vancomycin and Vancocin for use in treating C. difficile-associated diarrhea and enterocolitis. Further, it provides contract manufacturing services for other pharmaceutical companies. The company markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ANIP
CUSIPN/A
Phone218-634-3500
Debt
Debt-to-Equity Ratio1.11
Current Ratio3.62
Quick Ratio2.75
Price-To-Earnings
Trailing P/E Ratio17.68
Forward P/E Ratio11.76
P/E GrowthN/A
Sales & Book Value
Annual Sales$176.84 million
Price / Sales4.26
Cash Flow$5.9266 per share
Price / Cash10.77
Book Value$14.99 per share
Price / Book4.26
Profitability
EPS (Most Recent Fiscal Year)$3.61
Net Income$-1,070,000.00
Net Margins0.01%
Return on Equity27.16%
Return on Assets12.43%
Miscellaneous
Employees173
Outstanding Shares11,800,000
ANI Pharmaceuticals (NASDAQ:ANIP) Frequently Asked Questions
What is ANI Pharmaceuticals' stock symbol?
ANI Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANIP."
How were ANI Pharmaceuticals' earnings last quarter?
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its earnings results on Tuesday, May, 8th. The specialty pharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.28 by $0.04. The specialty pharmaceutical company had revenue of $46.48 million for the quarter, compared to analysts' expectations of $49.93 million. ANI Pharmaceuticals had a return on equity of 27.16% and a net margin of 0.01%. ANI Pharmaceuticals's quarterly revenue was up 26.9% compared to the same quarter last year. During the same period last year, the business earned $0.74 EPS. View ANI Pharmaceuticals' Earnings History.
What guidance has ANI Pharmaceuticals issued on next quarter's earnings?
ANI Pharmaceuticals issued an update on its FY18 earnings guidance on Tuesday, May, 8th. The company provided EPS guidance of $5.43-6.08 for the period, compared to the Thomson Reuters consensus estimate of $5.55. The company issued revenue guidance of $212-228 million, compared to the consensus revenue estimate of $215.67 million.
What price target have analysts set for ANIP?
2 analysts have issued 1 year price targets for ANI Pharmaceuticals' shares. Their forecasts range from $80.00 to $82.00. On average, they expect ANI Pharmaceuticals' stock price to reach $81.00 in the next year. View Analyst Ratings for ANI Pharmaceuticals.
What are Wall Street analysts saying about ANI Pharmaceuticals stock?
Here are some recent quotes from research analysts about ANI Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company. It engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The company offers liquid, powder, oral solid dose, cough/cold products, antacids, laxatives, stomach remedies as well as hydrocortisone retention enema, esterified estrogen and methyltestosterone, fluvoxamine maleate tablets, hydrocortisone rectal suspension, metoclopramide oral solution, opium tincture and metoclopramide tablets. In addition, it offers contract manufacturing services for other pharmaceutical companies. The company serves through wholesalers, smaller regional distributors and chains and pharmacy and retail outlets primarily in the United States. ANI Pharmaceuticals, Inc., formerly known as BioSante Pharmaceuticals, Inc., is headquartered in Baudette, MN. " (5/14/2018)
- 2. Canaccord Genuity analysts commented, "We remain pessimistic about the company’s ability to execute a successful clinical trial required for FDA approval. The planned 2018 $10M cost-cutting initiative suggests to us that Eagle isn’t too confident either (and is generally in line with our expectations). Eagle’s other pipeline programs like fulvestrant and drug-induced hyperthermia are questionable and may require a few more years of development under a best case scenario, in our view. There was strangely no mention of the Alimta RTD PDUFA in October. Eagle also reiterated prior 2017 expense guidance of $50-$53M in SG&A (excluding stock based comp) and $26- $30M R&D (excluding stock-based comp). We note the company was previously reporting GAAP earnings so the change is slightly new. We also note that Eagle has expanded its borrowing capacity by $100M (suggesting to us that it may want to bring in new assets) but simultaneously announced an additional $100M buyback program." (8/9/2017)
Who are some of ANI Pharmaceuticals' key competitors?
Some companies that are related to ANI Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are ANI Pharmaceuticals' key executives?
ANI Pharmaceuticals' management team includes the folowing people:
- Mr. Arthur S. Przybyl, Chief Exec. Officer, Pres and Director (Age 61)
- Mr. Stephen P. Carey, Chief Financial Officer and VP of Fin. (Age 47)
- Mr. James G. Marken, Sr. VP of Operations & Product Devel. (Age 55)
- Mr. Robert W. Schrepfer, Sr. VP of Bus. Devel. & Specialty Sales (Age 46)
- Dr. David J. Sullivan Ph.D., VP of Quality Operations
Has ANI Pharmaceuticals been receiving favorable news coverage?
News coverage about ANIP stock has been trending somewhat positive on Monday, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. ANI Pharmaceuticals earned a coverage optimism score of 0.09 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 47.37 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are ANI Pharmaceuticals' major shareholders?
ANI Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.05%), Dimensional Fund Advisors LP (3.99%), LSV Asset Management (2.61%), Northern Trust Corp (0.96%), Allianz Asset Management GmbH (0.72%) and Cortina Asset Management LLC (0.71%). Company insiders that own ANI Pharmaceuticals stock include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Institutional Ownership Trends for ANI Pharmaceuticals.
Which institutional investors are selling ANI Pharmaceuticals stock?
ANIP stock was sold by a variety of institutional investors in the last quarter, including Cortina Asset Management LLC, Allianz Asset Management GmbH, ETRADE Capital Management LLC, Chicago Equity Partners LLC, Schwab Charles Investment Management Inc., Northern Trust Corp, American International Group Inc. and Piermont Capital Management Inc.. Company insiders that have sold ANI Pharmaceuticals company stock in the last year include Arthur Przybyl, Daniel Raynor, James G Marken, Robert W Schrepfer and Tracy Marshbanks. View Insider Buying and Selling for ANI Pharmaceuticals.
Which institutional investors are buying ANI Pharmaceuticals stock?
ANIP stock was purchased by a variety of institutional investors in the last quarter, including LSV Asset Management, Millennium Management LLC, Matarin Capital Management LLC, Mackay Shields LLC, A.R.T. Advisors LLC, BlackRock Inc., Argent Capital Management LLC and Cubist Systematic Strategies LLC. View Insider Buying and Selling for ANI Pharmaceuticals.
How do I buy shares of ANI Pharmaceuticals?
Shares of ANIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ANI Pharmaceuticals' stock price today?
One share of ANIP stock can currently be purchased for approximately $63.83.
How big of a company is ANI Pharmaceuticals?
ANI Pharmaceuticals has a market capitalization of $760.02 million and generates $176.84 million in revenue each year. The specialty pharmaceutical company earns $-1,070,000.00 in net income (profit) each year or $3.61 on an earnings per share basis. ANI Pharmaceuticals employs 173 workers across the globe.
How can I contact ANI Pharmaceuticals?
ANI Pharmaceuticals' mailing address is 210 Main Street West, Baudette MN, 56623. The specialty pharmaceutical company can be reached via phone at 218-634-3500 or via email at [email protected]
MarketBeat Community Rating for ANI Pharmaceuticals (ANIP)
MarketBeat's community ratings are surveys of what our community members think about ANI Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
ANI Pharmaceuticals (NASDAQ:ANIP) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
2 Wall Street analysts have issued ratings and price targets for ANI Pharmaceuticals in the last 12 months. Their average twelve-month price target is $81.00, suggesting that the stock has a possible upside of 26.90%. The high price target for ANIP is $82.00 and the low price target for ANIP is $80.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 2.67 | 2.67 | 2.67 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $81.00 | $72.6667 | $71.00 | $67.3333 |
| Price Target Upside: | 26.90% upside | 20.31% upside | 11.62% upside | 12.02% upside |
ANI Pharmaceuticals (NASDAQ:ANIP) Consensus Price Target History
ANI Pharmaceuticals (NASDAQ:ANIP) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
ANI Pharmaceuticals (NASDAQ:ANIP) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 33.10%
Institutional Ownership Percentage: 61.35%
ANI Pharmaceuticals (NASDAQ ANIP) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/16/2018 | Tracy Marshbanks | Director | Sell | 38,236 | $62.33 | $2,383,249.88 | |  |
| 5/10/2018 | Tracy Marshbanks | Director | Sell | 62,431 | $62.07 | $3,875,092.17 | | |
| 4/18/2018 | Tracy Marshbanks | Director | Sell | 33,200 | $62.09 | $2,061,388.00 | | |
| 3/19/2018 | Daniel Raynor | Director | Sell | 7,215 | $60.85 | $439,032.75 | | |
| 3/14/2018 | Arthur Przybyl | Insider | Sell | 40,000 | $61.83 | $2,473,200.00 | 225,706 | |
| 3/14/2018 | Daniel Raynor | Director | Sell | 27,964 | $62.24 | $1,740,479.36 | | |
| 3/12/2018 | Tracy Marshbanks | Director | Sell | 64,221 | $63.03 | $4,047,849.63 | | |
| 3/8/2018 | Tracy Marshbanks | Director | Sell | 15,391 | $63.08 | $970,864.28 | | |
| 3/5/2018 | James G Marken | SVP | Sell | 4,177 | $61.92 | $258,639.84 | 66,439 | |
| 3/1/2018 | Robert W Schrepfer | SVP | Sell | 28,652 | $61.66 | $1,766,682.32 | 41,590 | |
| 8/22/2016 | Arthur Przybyl | Insider | Sell | 37,455 | $66.97 | $2,508,361.35 | 200,788 | |
| 8/8/2016 | Robert W Schrepfer | VP | Sell | 12,500 | $67.06 | $838,250.00 | 17,362 | |
| 12/18/2015 | James G Marken | VP | Sell | 3,500 | $43.26 | $151,410.00 | 45,983 | |
| 11/12/2015 | Arthur Przybyl | CEO | Buy | 2,500 | $40.95 | $102,375.00 | 145,195 | |
| 3/19/2015 | James G Marken | VP | Sell | 15,000 | $66.50 | $997,500.00 | | |
| 9/15/2014 | Ross J Mangano | Director | Buy | 3,000 | $27.49 | $82,470.00 | | |
| 9/9/2014 | Arthur Przybyl | CEO | Buy | 1,000 | $26.50 | $26,500.00 | | |
| 6/18/2014 | James G Marken | VP | Sell | 5,000 | $34.28 | $171,400.00 | | |
| 5/8/2014 | Tracy Marshbanks | Director | Sell | 1,381 | $30.02 | $41,457.62 | | |
| 5/7/2014 | Ross Mangano | Director | Buy | 2,000 | $30.38 | $60,760.00 | 23,914 | |
| 3/21/2014 | Tracy Marshbanks | Director | Sell | 21,767 | $31.42 | $683,919.14 | | |
| 3/20/2014 | Meridian Venture Partners Ii L | major shareholder | Sell | 20,922 | $32.12 | $672,014.64 | | |
| 3/19/2014 | Tracy Marshbanks | Director | Sell | 25,358 | $33.68 | $854,057.44 | | |
| 3/18/2014 | Meridian Venture Partners Ii L | major shareholder | Sell | 60,540 | $34.07 | $2,062,597.80 | | |
| 3/13/2014 | Meridian Venture Partners Ii L | major shareholder | Sell | 87,723 | $32.48 | $2,849,243.04 | | |
| 11/7/2013 | Ross J Mangano | Director | Buy | 9,000 | $11.27 | $101,430.00 | | |
| 8/20/2013 | Ross J Mangano | Director | Buy | 10,000 | $7.47 | $74,700.00 | | |
(Data available from 1/1/2013 forward)
ANI Pharmaceuticals (NASDAQ ANIP) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | ANI Pharmaceuticals, Inc. (ANIP) Director Sells $2,383,249.88 in Stock
www.americanbankingnews.com - May 16 at 7:17 PM |
 | Form 8-K ANI PHARMACEUTICALS INC For: May 16
www.streetinsider.com - May 16 at 4:56 PM |
 | What Does ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Share Price Indicate?
finance.yahoo.com - May 15 at 5:14 PM |
| Zacks Investment Research Upgrades ANI Pharmaceuticals (ANIP) to "Buy"
www.americanbankingnews.com - May 14 at 5:24 PM |
| ANI Pharmaceuticals (ANIP) Lifted to "Hold" at BidaskClub
www.americanbankingnews.com - May 11 at 9:17 PM |
| ANI Pharmaceuticals, Inc. (ANIP) Director Sells $3,875,092.17 in Stock
www.americanbankingnews.com - May 11 at 7:25 PM |
| Edited Transcript of ANIP earnings conference call or presentation 8-May-18 2:30pm GMT
finance.yahoo.com - May 10 at 9:08 AM |
| ANI Pharmaceuticals (ANIP) Given a $82.00 Price Target by Canaccord Genuity Analysts
www.americanbankingnews.com - May 9 at 12:08 PM |
 | ANI Pharmaceuticals' (ANIP) CEO Arthur Przybyl on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 9 at 9:03 AM |
| ANI Pharmaceuticals beats by $0.04, misses on revenue
seekingalpha.com - May 8 at 4:55 PM |
| ANI: 1Q Earnings Snapshot
finance.yahoo.com - May 8 at 4:55 PM |
| ANI Pharmaceuticals (ANIP) Posts Earnings Results, Beats Estimates By $0.04 EPS
www.americanbankingnews.com - May 8 at 12:13 PM |
 | ANI Pharmaceuticals, Inc. Q1 adjusted earnings Beat Estimates
www.nasdaq.com - May 8 at 8:57 AM |
| ANI Pharmaceuticals Reports First Quarter 2018 Results and Reaffirms Guidance
finance.yahoo.com - May 8 at 8:57 AM |
| ANI Pharmaceuticals (ANIP) Releases FY18 Earnings Guidance
www.americanbankingnews.com - May 8 at 8:56 AM |
| ANI Pharmaceuticals Completes Acquisition of Generic Products and Assets from Amneal/Impax
finance.yahoo.com - May 7 at 8:54 AM |
| ANI Pharmaceuticals (ANIP) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 2 at 8:47 PM |
| ANI Pharmaceuticals Schedules Conference Call to Discuss First Quarter 2018 Financial Results
finance.yahoo.com - May 1 at 9:03 AM |
| ANI Pharmaceuticals, Inc. (ANIP) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 29 at 1:34 AM |
| BidaskClub Lowers ANI Pharmaceuticals (ANIP) to Sell
www.americanbankingnews.com - April 25 at 12:58 AM |
| ANI Pharmaceuticals (ANIP) Earns Buy Rating from Guggenheim
www.americanbankingnews.com - April 19 at 11:52 PM |
| Tracy Marshbanks Sells 33,200 Shares of ANI Pharmaceuticals, Inc. (ANIP) Stock
www.americanbankingnews.com - April 19 at 7:20 PM |
| FDA OKs ANI Pharma's generic morphine oral solution
seekingalpha.com - April 18 at 5:07 PM |
 | BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution
www.reuters.com - April 18 at 9:01 AM |
| ANI Pharmaceuticals Announces Approval of Morphine Sulfate Oral Solution
finance.yahoo.com - April 18 at 9:01 AM |
| ANI Pharmaceuticals (ANIP) Now Covered by Analysts at Canaccord Genuity
www.americanbankingnews.com - April 15 at 9:45 AM |
| ANI Pharmaceuticals (ANIP) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - April 12 at 10:47 AM |
| ANI Pharmaceuticals (ANIP) Given Buy Rating at Canaccord Genuity
www.americanbankingnews.com - April 7 at 12:31 PM |
| ANI Pharma (ANIP) Buys 23 ANDAs from IDT Australia, Ltd.
www.streetinsider.com - April 4 at 3:39 PM |
| ANI Acquires 23 ANDAs from IDT Australia, Ltd.
finance.yahoo.com - April 4 at 9:04 AM |
| ANI Pharmaceuticals, Inc. (ANIP) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 4 at 1:40 AM |
| ANI Pharmaceuticals (ANIP) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - April 3 at 7:34 PM |
| Is ANI Pharmaceuticals Inc (NASDAQ:ANIP) A Financially Sound Company?
finance.yahoo.com - April 3 at 4:54 PM |
| ANI Pharmaceuticals (ANIP) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM |
| Canaccord Genuity Analysts Give ANI Pharmaceuticals (ANIP) a $82.00 Price Target
www.americanbankingnews.com - March 24 at 5:43 PM |
| ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 7,215 Shares
www.americanbankingnews.com - March 19 at 7:30 PM |
| Where ANI Pharmaceuticals Inc’s (NASDAQ:ANIP) Earnings Growth Stands Against Its Industry
finance.yahoo.com - March 16 at 9:11 AM |
| ANI Pharmaceuticals Inc (ANIP) Director Daniel Raynor Sells 27,964 Shares
www.americanbankingnews.com - March 14 at 7:11 PM |
| ANI Pharmaceuticals Inc (ANIP) Insider Sells $2,473,200.00 in Stock
www.americanbankingnews.com - March 14 at 7:10 PM |
 | Should Value Investors Pick ANI Pharmaceuticals (ANIP) Stock?
www.zacks.com - March 14 at 9:44 AM |
| Tracy Marshbanks Sells 15,391 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM |
| Tracy Marshbanks Sells 64,221 Shares of ANI Pharmaceuticals Inc (ANIP) Stock
www.americanbankingnews.com - March 12 at 10:28 PM |
| ANI Pharmaceuticals Inc (ANIP) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 10 at 1:28 AM |
| Wired News – Aptose Biosciences Inked Exclusive License Agreement with OHM Oncology for APL-581
finance.yahoo.com - March 9 at 9:22 AM |
| ANI Pharmaceuticals (ANIP) Presents At Raymond James 39th Annual Institutional Investors Conference - Slideshow
seekingalpha.com - March 8 at 5:52 PM |
| Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 4,177 Shares of Stock
www.americanbankingnews.com - March 7 at 6:50 PM |
| ANI Pharmaceuticals Inc (ANIP) Holdings Increased by Ranger Investment Management L.P.
www.americanbankingnews.com - March 6 at 2:11 PM |
| Insider Selling: ANI Pharmaceuticals Inc (ANIP) SVP Sells 28,652 Shares of Stock
www.americanbankingnews.com - March 5 at 6:22 PM |
| ANI Pharmaceuticals (ANIP) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 3 at 6:07 PM |
| ANI Pharmaceuticals to Present at the Raymond James 39th Annual Institutional Investors Conference
finance.yahoo.com - March 2 at 8:56 AM |
ANI Pharmaceuticals (NASDAQ:ANIP) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ANI Pharmaceuticals (NASDAQ:ANIP) Income Statement, Balance Sheet and Cash Flow Statement
ANI Pharmaceuticals (NASDAQ ANIP) Stock Chart for Monday, May, 21, 2018
Loading chart…
